10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

FGF-basic

Catalog # PVGS1686

Product Information

Primary Accession	XP_035600424.1
Species	Salmon
Sequence	Full length
Purity	≥ 95% as analyzed by SDS-PAGE
Endotoxin Level	
Biological Activity	$EC_{50\ 50}$, the calculated specific activity is approximately > 1.0×10^6 IU/mg. It is recommended to experimentally determine the optimal concentration for each specific application by performing a dose response assay.
Expression System	E. coli
Theoretical Molecular Weight	17.1 kDa
Formulation	Lyophilized from a 0.2 μm filtered solution in 7.8 mM Na_2HPO_4, 1.5 mM KH_2PO_4, 2.7 mM KCl, 500 mM NaCl.
Reconstitution	Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in PBS up to 100 μg/ml.
Storage & Stability	Upon receiving, the lyophilized product remains stable for up to 6 months at lower than -70 °C. Upon reconstitution, the product is stable for up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles by making single-use aliquots before the solution is storage at -20 °C.

Additional Information

Target Background	Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a pleiotropic cytokine and one of the prototypic members of the heparin-binding FGF family. Like other FGF family members, FGF-basic has the β trefoil structure. In vivo, FGF-basic is produced by a variety of cells, including cardiomyocytes, fibroblasts, and vascular cells. FGF-basic regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. FGF-basic can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of FGF-basic can produce beneficial cardioprotection during acute heart injury.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.